Heald AH, Martin JL, Payton T, Khalid L, Anderson SG, Narayanan RP, De Hert M, Yung A, Livingston M. Changes in metabolic parameters in patients with severe mental illness over a 10-year period: a retrospective cohort study. Aust N Z J Psychiatry. 2017;51:75–82.

Article  PubMed  Google Scholar 

Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205–18.

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–96.

Article  CAS  PubMed  Google Scholar 

Cooper SJ, Reynolds GP; With expert co-authors (in alphabetical order): Barnes T, England E, Haddad PM, Heald A, Holt R, Lingford-Hughes A, Osborn D, McGowan O, Patel MX, Paton C, Reid P, Shiers D, Smith J. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30:717–48.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiat. 2014;71:1350–63.

Article  Google Scholar 

Harrison RNS, Gaughran F, Murray RM, Lee SH, Cano JP, Dempster D, Curtis CJ, Dima D, Patel H, de Jong S, Breen G. Development of multivariable models to predict change in Body Mass Index within a clinical trial population of psychotic individuals. Sci Rep. 2017;7:14738.

Heald A, Daly C, Warner-Levy JJ, Williams R, Meehan C, Livingston M, Pillinger T, Hussain L, Firth J. Weight change following diagnosis with psychosis: a retrospective cohort study in Greater Manchester. UK Ann Gen Psychiatry. 2024;23:1.

Article  PubMed  Google Scholar 

Brandl EJ, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry. 2014;59:76–8.

Article  PubMed  PubMed Central  Google Scholar 

Perkins AJ, Khandker R, Overley A, Solid CA, Chekani F, Roberts A, Dexter P, Boustani MA, Hulvershorn L. Association of antipsychotic-related weight gain with treatment adherence and switching using electronic medical records data. Prim Care Compan CNS Disord. 2023;9:25.

Google Scholar 

Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, Lieberman JA. The impact of obesity on health care costs among persons with schizophrenia. Gen Hosp Psychiatry. 2009;31:1–7.

Article  PubMed  Google Scholar 

Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, Rosenkilde M, Bogh AF, Gliemann L, Jensen JB, Antoniades C, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22:41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–16.

https://icd.who.int/browse10/2019/en. Accessed 24 Jan 2025.

https://www.legislation.gov.uk/ukpga/1983/20/contents. Accessed 31 Dec 2024.

https://www.nice.org.uk/guidance/ta875. Accessed 24 Jan 2025.

https://euroqol.org/information-and-support/euroqol-instruments/eq-5d-5l. Accessed 1 Feb 2025.

Perkins AJ, Khandker R, Overley A, et al. Association of antipsychotic- related weight gain with treatment adherence and switching using electronic medical records data. Prim Care Compan CNS Disord. 2023;25:2203310.

Article  Google Scholar 

McIntyre RS, Kwan ATH, Rosenblat JD, Teopiz KM, Mansur RB. Psychotropic drug-related weight gain and its treatment. Am J Psychiatry. 2024;1(18):26–38.

Article  Google Scholar 

Kolotkin RL, Corey-Lisle PK, Crosby RD, Swanson JM, Tuomari AV, L’italien GJ, Mitchell JE. Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity (Silver Spring). 2008;16:749–54.

Article  PubMed  Google Scholar 

Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6:675–712.

Article  PubMed  Google Scholar 

Mazereel V, Detraux J, Vancampfort D, et al. Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness. Front Endocrinol (Lausanne). 2020;11: 573479.

Article  PubMed  Google Scholar 

Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163–80.

Article  PubMed  PubMed Central  Google Scholar 

Uusitupa M, Khan TA, Viguiliouk E, Kahleova H, Rivellese AA, Hermansen K, Pfeiffer A, Thanopoulou A, Salas-Salvadó J, Schwab U, Sievenpiper JL. Prevention of type 2 diabetes by lifestyle changes: a systematic review and meta-analysis. Nutrients. 2019;11:2611.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sinning C, Makarova N, Völzke H, Schnabel RB, Ojeda F, Dörr M, Felix SB, Koenig W, Peters A, Rathmann W, Schöttker B, Brenner H, Veronesi G, Cesana G, Brambilla P, Palosaari T, Kuulasmaa K, Njølstad I, Mathiesen EB, Wilsgaard T, Blankenberg S, Söderberg S, Ferrario MM, Thorand B. Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium. Cardiovasc Diabetol. 2021;20:223.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miley KM, Hooker SA, Crain AL, O’Connor PJ, Haapala JL, Bond DJ, Rossom RC. 30-year cardiovascular disease risk for young adults with serious mental illness. Gen Hosp Psychiatry. 2023;85:139–47. https://doi.org/10.1016/j.genhosppsych.2023.

Article  PubMed  PubMed Central  Google Scholar 

https://www.legislation.gov.uk/ukpga/1983/20/contents. Accessed 1 Feb 2025.

Monney M, Jornayvaz FR, Gariani K. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes Metab. 2023;49:10147.

Article  Google Scholar 

Jerlhag E. Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. Brain Res. 2020;1727:14656230.

Article  Google Scholar 

Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, Marchette RC, Koob GF, Roberto M, Vendruscolo LF, Leggio L. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8: e170671.

Article  PubMed  PubMed Central  Google Scholar